By David Alain Wohl, MD
While it’s not new, injected, implanted, or even prohibitively expensive, it is the medication studied in the most important HIV-related clinical trial of the year, if not the decade. The National Institutes of Health–sponsored, placebo-controlled REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) trial examined whether pitavastatin, a moderately potent statin with minimal antiretroviral drug interactions, can prevent cardiovascular events in people with HIV who are 40 to 75 years old and not predicted to be at high risk for cardiovascular disease.
Read the full article here.
